Latham Advises TPG on Acquisition of Majority Interest in DOC Generici

Latham & Watkins has advised TPG Capital, the private equity platform of global alternative asset management firm TPG, on its acquisition of a majority interest in Diocle Topco S.àr.l., parent of DOC Generici, a leading generic pharmaceutical company based in Milan, from ICG and Merieux Equity Partners. The closing of the transaction is subject to the satisfaction of customary regulatory conditions.

The transaction represents the fourth significant European pharmaceutical deal that Latham has advised on this year, having previously represented Astorg on its acquisition of CordenPharma, CVC on the sale of Theramex, and Norgine on its sale to Goldman Sachs Asset Management.

The Latham team was led by London partner Robbie McLaren and Milan partner Giovanni Sandicchi, with London associate Samantha Peacock and Milan associates Maria Giulia De Cesari, Marco Martino, and Mattia Siena. Advice was also provided on finance matters by London partners Jay Sadanandan and Francesco Lione and Milan partner Marcello Bragliani, with London associates William Lam, James Fawcett, Andrii Fokin, Zahra Haji, Lucy Haworth, and Rosie Wu, and Milan associate Erika Brini Raimondi; on regulatory matters by Milan counsel Cesari Milani, with Milan associate Edoardo Cassinelli and London associate Brett Shandler; and on tax matters by London partner Karl Mah, with associate Richard Liu.